[1]刘少璇,李 佳,刘芳媛,等.基于“亢害承制”理论辨析卵巢癌因机证治[J].陕西中医杂志,2022,(7):925-928.[doi:DOI:10.3969/j.issn.1000-7369.2022.07.027]
　LIU Shaoxuan,LI Jia,LIU Fangyuan,et al.An analysis of mechanism in ovarian cancer based on the theory of “restraining excessiveness to acquire harmony”[J].,2022,(7):925-928.[doi:DOI:10.3969/j.issn.1000-7369.2022.07.027]
点击复制

基于“亢害承制”理论辨析卵巢癌因机证治
分享到：

《陕西中医》杂志[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2022年7期
页码:
925-928
栏目:
学术探讨
出版日期:
2022-07-05

文章信息/Info

Title:
An analysis of mechanism in ovarian cancer based on the theory of “restraining excessiveness to acquire harmony”
作者:
刘少璇1; 李 佳1; 刘芳媛1; 韩凤娟2
(1.黑龙江中医药大学,黑龙江 哈尔滨 150040; 2.黑龙江中医药大学附属第一医院妇科,黑龙江 哈尔滨 150040)
Author(s):
LIU Shaoxuan; LI Jia; LIU Fangyuan; HAN Fengjuan
(Heilongjiang University of Chinese Medicine,Harbin 150040,China)
关键词:
卵巢癌;  亢害承制;  五行生克;  因机证治;  病理机制;  病理产物
Keywords:
Ovarian cancer;  Restraining excessiveness to acquire harmony;  Gneration-inhibition in five elements;  Base on the identification of disease pathogenesis;  Pathological;  Pathological products
分类号:
R 737.31
DOI:
DOI:10.3969/j.issn.1000-7369.2022.07.027
文献标志码:
A
摘要:
现基于“亢害承制”理论探讨卵巢癌发病机制,认为本病以体虚为承制不及之“本”,加之各诱因亢盛而形成多种病理产物之“害”为主要病机,并基于此提出“调整盛衰,以平为期”的治疗总则,即五行生克以固不及、攻坚抑瘤以平其亢、鉴别“反兼化”抓住症状本质,从而达到治疗卵巢癌的目的,以期为传统医学治疗卵巢癌提供新思路。
Abstract:
Based on the theory of “restraining excessiveness to acquire harmony” to explore the pathogenesis of ovarian cancer,it is believed that the main pathogenesis of this disease is the deficiency of the body,and the “harm” of various pathological products formed by the hyperactivity of each inducement,and point a therapeutic principles is “correction the surfeits and deficits until achieving balance”,which include supplement vacuity via the theory of five-phase,dispel evils via the method of attack and expel,and distinguish the true and false vacuity and repletion,so as to achieve the purpose of treating ovarian cancer.In order to provide new ideas for the treatment of ovarian cancer in traditional medicine.

参考文献/References:

[1] Stewart C,Ralyea C,Lockwood S.Ovarian cancer:An integrated review[J].Seminars in Oncology Nursing,2019,35(2):151-156.
[2] 刘 维.从“亢害承制”论系统性红斑狼疮因机治要[J].中华中医药杂志,2013,28(7):2004-2007.
[3] 李沛纯,吴深涛.从“亢害承制”理论思考消渴病[J].中国中医基础医学杂志,2015,21(6):638-639,643.
[4] 朱 文,汪 悦,谢 瑜,等.基于亢害承制理论探讨调肝理肺法治疗干燥综合征[J].中国中医基础医学杂志,2021,27(3):507-509.
[5] 王 冰.重广补注黄帝内经素问[M].北京:科学技术文献出版社,2011:319-320.
[6] 李 猛,马战平,刘华为.刘华为教授五行脏腑气机气化理论及其实践意义[J].陕西中医,2014,35(7):889-891.
[7] 吴晓晴,卢雯平.从阳虚体质探讨卵巢癌发病机制和治疗[J].中国医药导报,2020,17(34):123-126.
[8] Flaum N,Crosbie EJ,Edmondson RJ,et al.Epithelial ovarian cancer risk:A review of the current genetic landscape[J].Clinical Genetics,2020,97(1):54-63.
[9] Ingham SL,Warwick J,Buchan I,et al.Ovarian cancer among 8005 women from a breast cancer family history clinic:No increased risk of invasive ovarian cancer in families testing negative for brca1 and brca2[J].Journal of Medical Genetics,2013,50(6):368-372.
[10] 林表君,张还珠.恶性肿瘤患者相关情绪障碍研究进展[J].中华肿瘤防治杂志,2020,27(24):2006-2012.
[11] Shi LF,Wu Y,Li CY.Hormone therapy and risk of ovarian cancer in postmenopausal women:A systematic review and meta-analysis[J].Menopause,2016,23(4):417-424.
[12] Blank MM,Wentzensen N,Murphy MA,et al.Dietary fat intake and risk of ovarian cancer in the nih-aarp diet and health study[J].British Journal of Cancer,2012,106(3):596-602.
[13] Larsson SC,Orsini N,Wolk A.Milk,milk products and lactose intake and ovarian cancer risk:A meta-analysis of epidemiological studies[J].International Journal of Cancer,2006,118(2):431-441.
[14] 周仲瑛,程海波,周学平,等.中医药辨治肿瘤若干理念问题的探讨[J].南京中医药大学学报,2014,30(2):101-104.
[15] 李冬华,周 杰.张锡纯治疗妇科癥瘕理法方药探析及应用[J].中国中医基础医学杂志,2019,25(10):1430-1432,1438.
[16] Garcia-Martinez E,Redondo A,Piulats JM,et al.Are antiangiogenics a good “partner” for immunotherapy in ovarian cancer?[J].Angiogenesis,2020,23(4):543-557.
[17] 张 帅,刘 胜.从“风痰瘀毒”论治三阴性乳腺癌[J].中国中医基础医学杂志,2018,24(1):31-33.
[18] 赵延华.周仲瑛辨治宫颈癌与卵巢癌学术传承及创新研究[D].南京:南京中医药大学,2019.
[19] 王爱华,康德英,王丽峰.辨证治疗妇科手术后发热[J].山东中医杂志,1999,18(7):18-19.
[20] 周晴晴,李慧杰,李秀荣.基于癌毒理论探讨攻毒治法抗肿瘤血管生成[J].陕西中医,2020,41(8):1134-1138.
[21] 李佳殷,林丽珠.林丽珠治疗卵巢癌经验[J].中医杂志,2012,53(21):1866-1867.
[22] 杨才志,黄仲羽,林洁涛,等.林丽珠治疗卵巢癌用药规律探讨[J].广州中医药大学学报,2019,36(12):2027-2033.
[23] 刘明明,熊墨年,丁 舸,等.熊墨年辨治卵巢癌用药规律分析[J].河南中医,2020,40(8):1182-1189.
[24] 杨美清,刘海涛,杨 蕴,等.基于数据挖掘的田建辉治疗妇科癌用药规律研究[J].上海中医药杂志,2020,54(5):61-65.
[25] 沈 影,韩凤娟,王秀霞.“温煦肾阳,搜剔胞络瘀滞”理论提出、应用及发展的思考[J].中华中医药杂志,2020,35(3):1336-1339.
[26] 文 敏,周 欣,赵 超,等.中药抗卵巢癌作用及机制研究新进展[J].天然产物研究与开发,2021,33(3):521-533.
[27] 滕 然,蒋益兰.活血化瘀在防治恶性肿瘤转移中的应用[J].陕西中医,2020,41(7):941-944.
[28] 张毅鹏,张金秋,洪月光.温阳利水方联合腹腔热灌注化疗治疗卵巢癌腹水临床观察及作用机制研究[J].四川中医,2018,36(6):157-160.

相似文献/References:

[1]常丰葛,张 珂,马玉瑶,等.白花蛇舌草提取物对卵巢癌模型大鼠的疗效及对其血清性激素水平的影响*[J].陕西中医杂志,2019,(6):687.
　CHANG Fengge,ZHANG Ke,MA Yuyao,et al.Effect of hedyotis diffusa extract on ovarian cancer model rats and its effect on serum sex hormone levels[J].,2019,(7):687.
[2]王沈峰,金 迎,周禄荣,等.益气活血法治疗卵巢癌及对患者血清人附睾蛋白4、间皮素及肿瘤标记物的影响研究*[J].陕西中医杂志,2020,(5):646.[doi:DOI:10.3969/j.issn.10007369.2020.05.026]
　WANG Shenfeng,JIN Ying,ZHOU Lurong,et al.Yiqi Huoxue method in the treatment of ovarian cancer and effects on serum HE4,SMRP and tumor markers[J].,2020,(7):646.[doi:DOI:10.3969/j.issn.10007369.2020.05.026]
[3]胡天祺,杨梦琪,杨 红,等.益气养阴方对卵巢癌术后患者化疗不良反应及生存质量的影响[J].陕西中医杂志,2021,(4):434.[doi:DOI:10.3969/j.issn.1000-7369.2020.04.007]
　HU Tianqi,YANG Mengqi,YANG Hong,et al.Effect of Yiqi Yangyin recipe on the adverse reaction effects and quality of life in patients with ovarian cancer undergoing chemotherapy[J].,2021,(7):434.[doi:DOI:10.3969/j.issn.1000-7369.2020.04.007]
[4]李成斐,朱 萍,于 佳,等.益气活血解毒方联合化疗治疗晚期卵巢癌疗效及对患者免疫通路相关靶基因的影响[J].陕西中医杂志,2021,(8):1072.[doi:DOI:10.3969/j.issn.1000-7369.2020.08.021]
　LI Chengfei,ZHU Ping,YU Jia,et al.The effect of Yiqi Huoxie Jiedu decoction combined with TC regimen on advanced ovarian cancer and related target genes of immune pathway[J].,2021,(7):1072.[doi:DOI:10.3969/j.issn.1000-7369.2020.08.021]
[5]王小玉,韩凤娟.基于“天癸-肾阳-命门”学说探究卵巢癌发病机制[J].陕西中医杂志,2021,(9):1261.[doi:DOI:10.3969/j.issn.1000-7369.2020.09.029]
[6]陈双凤,吉亚南.温阳活血方对卵巢癌患者免疫指标及炎性因子的影响[J].陕西中医杂志,2021,(10):1371.[doi:DOI:10.3969/j.issn.1000-7369.2020.10.011]

备注/Memo

备注/Memo:
基金项目:国家自然科学基金资助项目(82074484)
更新日期/Last Update: 2022-07-07